Gilead’s Covid-19 Drug May Offer ‘Ray of Hope,’ Street Says
- Results from a small uncontrolled study not conclusive
- Timelines on larger studies out of China look further away
Remdesivir
Photographer: Ulrich Perrey/AFP via Getty Images
This article is for subscribers only.
Gilead Sciences Inc. rose Monday after results from a small set of Covid-19 patients getting the experimental therapy remdesivir. While acknowledging it was too early to tell if the medicine would work in larger studies, Evercore ISI called it “a ray of hope.”
Raymond James analysts were more critical. “We did our best to try and make sense of the small dataset and our conclusion is, unfortunately, remdesivir may not be doing much. We hope we’re wrong.”